Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Semaglutide (Wegovy) At the current maximum approved dose of 2.4 mg, estimated 68-week weight loss is around 17.0%, based on data from the 72 week STEP-UP trial
If you dont mind the daily routine, the oral medications are a great option, says Dr
Good Candidates BMI of 30 or higher (obesity) BMI of 27+ with weight-related conditions (high blood pressure, type 2 diabetes, high cholesterol) Previous unsuccessful attempts at diet and exercise alone Committed to lifestyle changes alongside medication Ready for regular physician monitoring Not Recommended For Personal or family history of medullary thyroid cancer Multiple Endocrine Neoplasia syndrome type 2 (MEN2) History of pancreatitis Pregnant or planning to become pregnant Currently breastfeeding Why Fort Worth Patients Choose Highland Longevity for Semaglutide Not all semaglutide providers are the same
Monitoring of volume status and renal parameters is advisable Poorly controlled hypertension , where the interaction between retatrutide and existing antihypertensive regimens may be unpredictable A history of pancreatitis : in line with UK Summary of Product Characteristics (SmPC) wording for approved GLP-1-based therapies such as semaglutide (Wegovy) and tirzepatide (Mounjaro), retatrutide should be used with caution in patients with a history of pancreatitis, and discontinued promptly if acute pancreatitis is suspected Thyroid C-cell tumours : rodent studies with GLP-1 receptor agonists have identified C-cell hyperplasia and tumours
10.1016/j.neuint.2015.06.003 51 WestermannB
Orders received over the weekend may not process for shipment until Monday
US$ 25.02
US$ 20.40
US$ 25.93
US$ 20.14
